(Q35010580)

5 August 2017

0 references

Regression of liver metastases of occult carcinoid tumor with slow release lanreotide therapy (English)

1 reference

5 August 2017

1 reference

Marta Bondanelli

1

1 reference

5 August 2017

Maria Rosaria Ambrosio

2

1 reference

5 August 2017

Maria Chiara Zatelli

3

1 reference

5 August 2017

Luigi Cavazzini

4

1 reference

5 August 2017

Laura Al Jandali Rifa'y

5

1 reference

5 August 2017

Ettore C degli Uberti

6

1 reference

5 August 2017

language of work or name

English

0 references

publication date

1 April 2005

1 reference

World Journal of Gastroenterology

5 August 2017

published in

1 reference

5 August 2017

volume

11

1 reference

5 August 2017

issue

13

1 reference

5 August 2017

page(s)

2041-2044

1 reference

Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system

5 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4305735

Somatostatin receptors in gastroentero-pancreatic neuroendocrine tumours

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4305735

Diagnosis and treatment of carcinoid tumors

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4305735

Somatostatin and Somatostatin Receptor Physiology

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4305735

A 5-decade analysis of 13,715 carcinoid tumors

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4305735

Somatostatin analogues in the treatment of endocrine tumors of the gastrointestinal tract

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4305735

Somatostatin receptor subtype 1-selective activation reduces cell growth and calcitonin secretion in a human medullary thyroid carcinoma cell line

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4305735

Regression of metastatic carcinoid tumors with octreotide therapy: two case reports and a review of the literature

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4305735

Identification of somatostatin receptor subtypes 1, 2A, 3, and 5 in neuroendocrine tumours with subtype specific antibodies

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4305735

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4305735

Induction of apoptosis in neuroendocrine tumors of the digestive system during treatment with somatostatin analogs

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4305735

Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours

8 July 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V11.I13.2041

Use of octreotide and lanreotide in the treatment of symptomatic non-resectable carcinoid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V11.I13.2041

An in vivo OctreoScan-negative adrenal pheochromocytoma expresses somatostatin receptors and responds to somatostatin analogs treatment in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V11.I13.2041

Proliferation of antigen MIB-1 in metastatic carcinoid tumours removed at liver transplantation: relevance to prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V11.I13.2041

Clinical significance of blood chromogranin A measurement in neuroendocrine tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V11.I13.2041

Treatment of gastroenteropancreatic neuroendocrine tumours with octreotide LAR

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4305735

Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian Trials in Medical Oncology Group

25 October 2018

1 reference

12 December 2020

Immunohistochemical expression of somatostatin type 2A receptor in neuroendocrine tumors

1 reference

12 December 2020

Complete histological regression of metastatic carcinoid tumour after treatment with octreotide

1 reference

12 December 2020

Somatostatin receptor subtype 1 selective activation in human growth hormone (GH)- and prolactin (PRL)-secreting pituitary adenomas: effects on cell viability, GH, and PRL secretion

1 reference

12 December 2020

1 reference

12 December 2020

Somatostatin receptors 2 and 5 are the major somatostatin receptors in insulinomas: an in vivo and in vitro study

1 reference

12 December 2020

Evaluation of patients with advanced cancer using the Karnofsky performance status

1 reference

12 December 2020

Cell biology, clinicopathological profile, and classification of gastro-enteropancreatic endocrine tumors

1 reference

12 December 2020

The somatostatin analogue octreotide inhibits neuroblastoma growth in vivo

1 reference

12 December 2020

High-dose treatment with lanreotide of patients with advanced neuroendocrine gastrointestinal tumors: clinical and biological effects

1 reference

12 December 2020

Long-term octreotide treatment of metastatic carcinoid tumor

1 reference

12 December 2020

Identifiers

DOI

10.3748/WJG.V11.I13.2041

1 reference

5 August 2017

1 reference

5 August 2017

1 reference